Literature DB >> 24614843

Long-term outcome and prognostic factors of unrelated cord blood transplantation in children with haematological malignancies: a retrospective study using the Spanish Working Party for BMT in Children (GETMON) database.

C Díaz de Heredia1, M González2, A Verdeguer3, I Elorza1, A Rodriguez4, A Martinez5, J M Pérez6, I Badell7, M E Gonzalez8, T Olivé1, J M Fernández3, M S Maldonado9, M A Díaz2, J Sánchez de Toledo1.   

Abstract

Outcomes of unrelated cord blood transplants (UCBT) were assessed in 172 consecutive children, median age 5 years (range: 0.5-18), with haematological malignancies treated at nine Spanish hospitals between February 1996 and April 2009. Data were collected from the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) database. ALL was diagnosed in 125 patients, AML in 43 and myelodysplastic syndrome in 4. Myeloid engraftment (ANC⩾0.5 × 10(9)/L) occurred in 87.2% at a median of 22 days and was associated with the total nucleated cell (TNC) dose infused and use of a TT-containing conditioning regimen. Cumulative incidence of relapse was 20% at 1 year post transplant and 29% at 3 years, being higher in patients with a diagnosis of ALL, very high risk disease and GVHD grades 0-1. Cumulative incidence of non-relapse mortality (NRM) was 19% at 100 days post transplant and 39% at 1 year. BU-FLU-TT-ATG-conditioned patients had lower NRM. Disease-free survival (DFS) was 40% at 2 years post transplant (for patients transplanted since 2006). On multivariate analysis, TNC dose infused, AML and BU-FLU-TT-ATG-conditioning regimen increased the probability of DFS. It is of paramount importance to select cord blood units with the highest cell dose. As the BU-FLU-TT-ATG-conditioning regimen was associated with better DFS owing to lower NRM, further prospective studies testing this regimen are warranted.

Entities:  

Mesh:

Year:  2014        PMID: 24614843     DOI: 10.1038/bmt.2014.30

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  41 in total

1.  Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

Authors:  Marcos de Lima; Ian McNiece; Simon N Robinson; Mark Munsell; Mary Eapen; Mary Horowitz; Amin Alousi; Rima Saliba; John D McMannis; Indreshpal Kaur; Partow Kebriaei; Simrit Parmar; Uday Popat; Chitra Hosing; Richard Champlin; Catherine Bollard; Jeffrey J Molldrem; Roy B Jones; Yago Nieto; Borje S Andersson; Nina Shah; Betul Oran; Laurence J N Cooper; Laura Worth; Muzaffar H Qazilbash; Martin Korbling; Gabriela Rondon; Stefan Ciurea; Doyle Bosque; Ila Maewal; Paul J Simmons; Elizabeth J Shpall
Journal:  N Engl J Med       Date:  2012-12-13       Impact factor: 91.245

2.  Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT.

Authors:  A Ruggeri; G Sanz; H Bittencourt; J Sanz; A Rambaldi; F Volt; I Yakoub-Agha; J M Ribera; L Mannone; J Sierra; M Mohty; C Solano; S Nabhan; W Arcese; E Gluckman; M Labopin; V Rocha
Journal:  Leukemia       Date:  2013-09-05       Impact factor: 11.528

3.  Cord blood transplantation from HLA-mismatched unrelated donors as a treatment for children with haematological malignancies.

Authors:  K Ohnuma; K Isoyama; K Ikuta; Y Toyoda; J Nakamura; F Nakajima; M Tsuchida; M Ohira; A Suminoe; T Hara; H Nishihira
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

4.  Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.

Authors:  J Sanz; J C H Boluda; C Martín; M González; C Ferrá; D Serrano; C D de Heredia; C Barrenetxea; A M Martinez; C Solano; M A Sanz; G F Sanz
Journal:  Bone Marrow Transplant       Date:  2012-02-13       Impact factor: 5.483

5.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.

Authors:  Colleen Delaney; Shelly Heimfeld; Carolyn Brashem-Stein; Howard Voorhies; Ronald L Manger; Irwin D Bernstein
Journal:  Nat Med       Date:  2010-01-17       Impact factor: 53.440

6.  A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation.

Authors:  Chunfu Li; Xuedong Wu; Xiaoqing Feng; Yuelin He; Huaying Liu; Fuyu Pei; Jianyu Liao; Lan He; Lei Shi; Na Li; Qiujun Liu; Shiting Liu; Geyu Chen; Qingxia Su; Yuqiong Ren; Yanhua Wang; Wanxia Tan
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

7.  Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor.

Authors:  G Bautista; J R Cabrera; C Regidor; R Forés; J A García-Marco; E Ojeda; I Sanjuán; E Ruiz; I Krsnik; B Navarro; S Gil; E Magro; A de Laiglesia; R Gonzalo-Daganzo; T Martín-Donaire; M Rico; I Millán; M N Fernández
Journal:  Bone Marrow Transplant       Date:  2008-10-13       Impact factor: 5.483

8.  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.

Authors:  Mary Eapen; Pablo Rubinstein; Mei-Jie Zhang; Cladd Stevens; Joanne Kurtzberg; Andromachi Scaradavou; Fausto R Loberiza; Richard E Champlin; John P Klein; Mary M Horowitz; John E Wagner
Journal:  Lancet       Date:  2007-06-09       Impact factor: 79.321

9.  Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia.

Authors:  Jaime Sanz; Miguel A Sanz; Silvana Saavedra; Ignacio Lorenzo; Pau Montesinos; Leonor Senent; Dolores Planelles; Luis Larrea; Guillermo Martín; Javier Palau; Isidro Jarque; Jesús Martínez; Javier de la Rubia; Federico Moscardó; Mónica Romero; Irene Luna; Alberto Montava; Sergio Cañabate; Guillermo F Sanz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-08       Impact factor: 5.742

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.